Picture of Dr. Changiz Taghibiglou

Dr. Changiz Taghibiglou PhD Faculty, Anatomy, Physiology & Pharmacology

Research Areas

  • Excitotoxicity-induced neuronal apoptosis in stroke and neurodegenerative diseases
  • Lipid rafts and neuronal receptor signaling and trafficking
  • Lipid Neurobiology
  • Brain insulin signaling pathways
  • Designing bioactive short peptides
  • Cellular and molecular mechanisms of traumatic brain injury/concussion
  • Biomarkers of traumatic brain injury/concussion

About Dr. Changiz Taghibiglou

Changiz Taghibiglou, Ph.D.

Associate Professor
Department of Anatomy, Physiology and Pharmacology
College of Medicine
University of Saskatchewan

Academic Credentials

  • Pharm. D. (first grade with honors), College of Pharmacy, Tabriz University of Medical Sciences, Tabriz-Iran
  • PhD, Department of Laboratory Medicine & Pathobiology (Clinical Biochemistry), University of Toronto, Canada

Post-doctoral Research

  • Neuroscience and Behavior Research Group, Hospital for Sick Children, University of Toronto, Canada
  • Brain Research Centre and Department of Medicine, University of British Columbia, Vancouver, Canada

Awards

  • Brain Star Award winner 2009, Canadian Institutes of Health Research (CIHR)
  • Canadian Institutes of Health Research (CIHR) fellowship (CAD $ 144,000)
  • Michael Smith Foundation for Health Research fellowship (CAD$ 115,000)

Selected Publications

  1. Sekar S, Zhang Y, Miranzadeh Mahabadi H, Parvizi A, Taghibiglou C. Low Field Magnetic Stimulation Restores Cognitive and Motor Functions in the Mouse Model of Repeated Traumatic Brain Injury: Role of Cellular Prion Protein. J Neurotrauma. 2019 Apr 25. doi: 10.1089/neu.2018.5918. [Epub ahead of print]. PMID: 31020907
  2. Tehse J, Taghibiglou C. The overlooked aspect of excitotoxicity: Glutamate-independent excitotoxicity in traumatic brain injuries. Eur J Neurosci. 2018 Dec 16. doi: 10.1111/ejn.14307. [Epub ahead of print] Review. PMID: 30554430
  3. Mohammad H, Sekar S, Wei Z, Moien-Afshari F, Taghibiglou C. Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus. Mol Neurobiol. 2019 Apr;56(4):2508-2523. doi: 10.1007/s12035-018-1230-6. Epub 2018 Jul 23. PMID: 30039334
  4. Sekar S, Taghibiglou C. Elevated nuclear phosphatase and tensin homolog (PTEN) and altered insulin signaling in substantia nigral region of patients with Parkinson's disease. Neurosci Lett. 2018 Feb 14; 666:139-143. doi: 10.1016/j.neulet.2017.12.049. Epub 2017 Dec 26. PMID: 29288045
  5. Sekar S, Omran E, Gopalakrishnan V, Howland JG, Snutch TP, Taghibiglou C. Elevated sterol regulatory elementary binding protein 1 and GluA2 levels in the hippocampal nuclear fraction of Genetic Absence Epilepsy Rats from Strasbourg. Epilepsy Res. 2017 Oct; 136:1-4. doi: 10.1016/j.eplepsyres.2017.07.004. Epub 2017 Jul 12. PMID: 28719803
  6. Tang M, Taghibiglou C. The Mechanisms of Action of Curcumin in Alzheimer's Disease. J Alzheimers Dis. 2017;58(4):1003-1016. doi: 10.3233/JAD-170188. Review. PMID: 28527218
  7. Siqingaowa, Sekar S, Gopalakrishnan V, Taghibiglou C. Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. Biochem Biophys Res Commun. 2017 Jun 17;488(1):136-140. doi: 10.1016/j.bbrc.2017.05.023. Epub 2017 May 5. PMID: 28483521
  8. Pham N, Akonasu H, Shishkin R, Taghibiglou C. Plasma soluble prion protein, a potential biomarker for sport-related concussions: a pilot study. PLoS One. 2015 Feb 2;10(2):e0117286. doi: 10.1371/journal.pone.0117286. eCollection 2015. PMID: 25643046
  9. Pham N, Sawyer TW, Wang Y, Jazii FR, Vair C, Taghibiglou C. Primary blast-induced traumatic brain injury in rats leads to increased prion protein in plasma: a potential biomarker for blast-induced traumatic brain injury. J Neurotrauma. 2015 Jan 1;32(1):58-65. doi: 10.1089/neu.2014.3471. PMID: 25058115
  10. Pham N, Dhar A, Khalaj S, Desai K, Taghibiglou C. Down regulation of brain cellular prion protein in an animal model of insulin resistance: possible implication in increased prevalence of stroke in pre-diabetics/diabetics. Biochem Biophys Res Commun. 2014 May 30;448(2):151-6. doi: 10.1016/j.bbrc.2014.04.071. Epub 2014 Apr 26. PMID: 24780399
  11. Stockwell J, Abdi N, Lu X, Maheshwari O, Taghibiglou C. Novel central nervous system drug delivery systems. Chem Biol Drug Des. 2014 May;83(5):507-20. doi: 10.1111/cbdd.12268. Epub 2014 Mar 14. Review. PMID: 24325540
  12. Zhang S, Taghibiglou C, Girling K, Dong Z, Lin SZ, Lee W, Shyu WC, Wang YT. Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal injuries. J Neurosci. 2013 May 1;33(18):7997-8008. doi: 10.1523/JNEUROSCI.5661-12.2013. PMID: 23637190
  13. Taghibiglou C, Lu J, Mackenzie IR, Wang YT, Cashman NR. Sterol regulatory element binding protein-1 (SREBP1) activation in motor neurons in excitotoxicity and amyotrophic lateral sclerosis (ALS): Indip, a potential therapeutic peptide. Biochem Biophys Res Commun. 2011 Sep 23;413(2):159-63. doi: 10.1016/j.bbrc.2011.08.011. Epub 2011 Aug 19. PMID: 21871872
  14. Taghibiglou C, Martin HG, Lai TW, Cho T, Prasad S, Kojic L, Lu J, Liu Y, Lo E, Zhang S, Wu JZ, Li YP, Wen YH, Imm JH, Cynader MS, Wang YT. Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat Med. 2009 Dec;15(12):1399-406. doi: 10.1038/nm.2064. Epub 2009 Nov 22. PMID:19966780
  15. Taghibiglou C, Bradley CA, Gaertner T, Li Y, Wang Y, Wang YT. Mechanisms involved in cholesterol-induced neuronal insulin resistance. Neuropharmacology. 2009 Sep;57(3):268-76. doi: 10.1016/j.neuropharm.2009.05.013. Epub 2009 Jun 10. PMID:19523477
  16. Taghibiglou C, Martin HG, Rose JK, Ivanova N, Lin CH, Lau HL, Rai S, Wang YT, Rankin CH. Essential role of SBP-1 activation in oxygen deprivation induced lipid accumulation and increase in body width/length ratio in Caenorhabditis elegans. FEBS Lett. 2009 Feb 18;583(4):831-4. doi: 10.1016/j.febslet.2009.01.045. Epub 2009 Jan 31. PMID: 19187779
  17. Bradley CA, Taghibiglou C, Collingridge GL, Wang YT. Mechanisms involved in the reduction of GABAA receptor alpha1-subunit expression caused by the epilepsy mutation A322D in the trafficking-competent receptor. J Biol Chem. 2008 Aug 8;283(32):22043-50. doi: 10.1074/jbc.M801708200. Epub 2008 Jun 5. PMID:18534981
  18. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007 Mar 1;53(5):703-17. PMID: 17329210
  19. Mielke JG, Taghibiglou C, Wang YT. Endogenous insulin signaling protects cultured neurons from oxygen-glucose deprivation-induced cell death. Neuroscience. 2006 Nov 17;143(1):165-73. Epub 2006 Sep 14. PMID:16978790
  20. Mielke JG, Taghibiglou C, Liu L, Zhang Y, Jia Z, Adeli K, Wang YT. A biochemical and functional characterization of diet-induced brain insulin resistance. J Neurochem. 2005 Jun;93(6):1568-78. PMID:15935073

Reviews

  1. Nasrollahi SA, Taghibiglou C, Azizi E, Farboud ES. Cell penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des. 2012 Jul 31. doi: 10.1111/cbdd.12008. [Epub ahead of print] PMID: 22846609
  2. Bradley CA, Peineau S, TaghibiglouC, Nicolas CS, Whitcomb DJ, Bortolotto ZA, Kaang BK, Cho K, Wang YT, Collingridge GL. A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci. 2012; 5: 13
  3. Stephane Peineau, Bradley C, Taghibiglou C,Wang YT and Collingridge GL. The role of GSK3 in synaptic plasticity. British Journal of Pharmacology.2008, 153:S428-37; PMID: 18311157
  4. Khosrow Adeli, Changiz Taghibiglou, Stephen C. Van Iderstine, and Gary F Lewis. Mechanisms Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance. Trends in Cardiovascular Medicine.2001, 11:170-176; PMID: 11597827.

Books and Book Chapters 

  1. Taghibiglou C (corresponding author) and Kalaj S 2017. Cholesterol and fat metabolism in Alzheimer’s disease (Chapter 9). In Drug discovery approaches for the treatment of neurodegenerative disorders-Alzheimer’s disease. Elsevier-Academic Press. ISBN:978-0-12-802810-0
  2. Kalaj S and Taghibiglou C (corresponding author) 2012. Role of lipid transcription factor, sterol regulatory element binding protein 1 (SREBP1) in ALS: Potential therapeutic interventions. Chapter 2 in Amyotrophic Lateral Sclerosis: Symptoms, Treatment and Prognosis (Editors:Katashi Segawa and Ryota Ijichi). Nova Publishing Company, New York (In Press). ISBN: 978-1-62257-679-1

Patents

  1. Taghibiglou C and U of S: Plasma Cellular Prion Protein (PrPC) as a biomarker for mild traumatic brain injuries and concussion 2014
  2. Taghibiglou C and U of S: Plasma ADAM10 as a biomarker for mild traumatic brain injuries and concussion 2015
  3. Taghibiglou C, Wang YT, and U of S, SREBP1 inhibiting bioactive peptide “Indip” for the treatment of Acne,  2012
  4. Wang YT, Taghibiglou C, and UBC: Indip, a novel peptide for treatment of brain trauma and stroke. US Patent filed on March 31, 2008.
  5. Therapeutic peptide for amyotrophic lateral sclerosis (Taghibiglou C, Wang YT, Cashman NR, and UBC; filed May 2 2009)
  6. Neuroprotective effects of PTEN-K13 peptide (Wang YT, Zhang S, and Taghibiglou C, and UBC; Global patent filed April 2011)